Fenretinide in Healthy Young Women at Genetic and Familial Risk
|First Received Date ICMJE||November 22, 2011|
|Last Updated Date||June 17, 2014|
|Start Date ICMJE||December 2009|
|Estimated Primary Completion Date||December 2024 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Breast cancer incidence [ Time Frame: every 6 months for 15 years ] [ Designated as safety issue: No ]
The aim of the proposed trial is to assess the efficacy of fenretinide, (4 hydroxyphenilretinamide, 4-HPR), a vitamin A derivative, in reducing the incidence of breast cancer (BC) in healthy young premenopausal women at increased familial/genetic risk for BC (i.e. BRCA1 or BRCA2 mutation carriers or subjects at high risk of being carriers). The primary endpoint is the incidence of invasive BC and ductal intraepithelial neoplasia (DIN), histologically diagnosed.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01479192 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Incidence of other non-invasive breast disorders, ovarian cancers and other cancers. [ Time Frame: every 6 months for 15 years ] [ Designated as safety issue: No ]
Incidence of other non-invasive breast disorders, ovarian cancers and other cancers.
Early intermediate biomarkers of efficacy after 12, 36, and 60 months of treatment. We will also evaluate the percent change in circulating biomarkers of the IGF system, androgens, retinol binding protein (RBP-4), insulin, blood glucose and VEGF, after 12, 36 and 60 months of treatment.
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Fenretinide in Healthy Young Women at Genetic and Familial Risk|
|Official Title ICMJE||Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial|
The purpose of this trial is to assess the effect of fenretinide (4-HPR), a vitamin A derivative, in reducing the incidence of breast cancer in healthy premenopausal women at increased familial/genetic risk for breast cancer
Retinoids have been studied as chemo preventive compounds in clinical trials because of their acknowledged role in regulating cell growth, differentiation and apoptosis in preclinical models. Induction of apoptosis is a unique feature of fenretinide (4-hydroxyphenylretinamide, 4-HPR),(2) the most widely studied retinoid in clinical trials of breast cancer chemoprevention for its selective accumulation in the breast tissue and its very low toxicity. The fifteen-year follow up of a randomized phase III trial of fenretinide to prevent second breast cancer indicates that fenretinide induced a 17%, durable reduction of second breast cancer incidence. When stratified by menopausal status, the analysis showed a 38%, statistically significant reduction of second breast cancers in premenopausal women and this protective effect persisted for up to 15 years, i.e. 10 years after treatment cessation. Importantly, the younger were the women, the greater was the trend of benefit of fenretinide, with a remarkable 50% risk reduction in women aged 40 years or younger, whereas the benefit disappeared after age 55. One explanation for the different effects of fenretinide according to menopausal status or age is a different modulation of circulating IGF-I in premenopausal and postmenopausal women, with a reduction of IGF-I levels only in premenopausal subjects.
When considering the protective activity of fenretinide on second breast cancer in young women and a similar trend on ovarian cancer (the latter at least during intervention)(4, 5), it appears that young women at high risk such as those with germ line BRCA-1 and 2 mutations or those with a high family risk may be ideal candidates for further investigation on this retinoid. Indeed, fenretinide is highly effective in inhibiting the growth of BRCA-1 mutated breast cancer cell lines. Since a reduction of second breast cancer might be a surrogate marker of primary prevention, a favourable effect of fenretinide provides strong rationale for a primary prevention trial in unaffected women at high-risk for breast cancer.
Importantly, at clinically relevant doses, fenretinide has shown to induce NO-mediated apoptosis in human and murine BRCA-1 mutated cancer cells, and In this ability fenretinide was the most potent of the phenylretinamide analogues against BRCA-1 mutated breast cancer cells.
Additionally, recent studies have shown that 4-HPR modulates gene expression in ovarian cells, with an up-regulation of expression of proapoptotic genes in OVCA433 cells and down-regulation of mutant BRCA genes in IOSE (premalignant) cells and OVCA433 cells. This suggests a preventive effect in premalignant cells and a treatment effect in cancer cells.
Increasing evidence sustains a link between the rising prevalence of metabolic syndrome in the Western world and breast cancer incidence. The retinol-binding protein 4 (RBP4), an adipocyte-secreted molecule, is the only specific transport protein for retinol in the blood and correlates with components of the metabolic syndrome, including increased body-mass index, waist-to-hip ratio, serum triglycerides. Plasma concentrations of RBP4 are known to decrease proportionally with retinol during fenretinide administration and normalization of RBP4 by fenretinide in insulin-resistant obese mice has shown to improve insulin action and glucose tolerance.
Among other molecular biomarker candidates for malignant tumours, cell-free DNA circulating in serum is very promising. Unlike uniformly truncated DNA released from apoptotic cells, DNA released from dead cancer cells varies in size. Serum DNA integrity and the ratio of longer fragments to total DNA may be clinically useful for detecting breast cancer progression. Since free-circulating DNA is a non-invasive approach and can be detected in cancer patients and not in disease-free individuals, it will be interesting to study if it can be used as an early detection biomarker.
Breast cancer chemoprevention is rapidly evolving, and there is strong evidence that primary chemoprevention is possible. The more established preventive agents so far are SERMs (selective estrogen receptor modulators), while AIs (aromatase inhibitors) are currently under investigation in postmenopausal populations. All these drugs involve directly the hormonal pathway of the pathogenesis of the disease, and their target is most likely limited to hormone responsive tumours. Tamoxifen has great effect as a chemo preventive agent but it may have serious side effects, while raloxifene may have a better toxicity profile, especially as concerns the risk of endometrial cancer, but it has been tested only in post menopause. Fenretinide has shown to possess several good properties both in preclinical models and clinical trials. In particular, the prolonged effect demonstrated in the phase III trial chemopreventive trial in breast cancer subjects, together with a trend of protective effect on the ovaries, has been accompanied by a very low toxicity profile (mainly reversible skin dryness and rashes and dark adaptation difficulties, often overcome by a monthly weekend suspension of the drug).
All these characteristics make fenretinide an excellent candidate for chemoprevention in a cohort of young healthy women with a high susceptibility to early onset breast and ovarian cancer, such as those who carry a BRCA 1/2 mutation or have a significant family risk. Since the drug activities are probably not strictly influenced by hormonal responsiveness, it is possible that it may have effect also on hormone non-responsive cancers, and this may be very useful particularly in case of BRCA1 mutation carriers.
Side effects and toxicity: visual symptoms (diminished dark adaptability, dryness and lacrimation) have been reported in approximately 20% of subjects. These symptoms may occur more frequently at the start of intervention and they tend to recover with time often without the need for treatment discontinuation. A regular three-days/month drug suspension has been adopted for a long time in clinical studies to minimize visual impairment. Although this side effect is in many women manageable (especially following the regular three day suspension) and reversible, it must be remembered that the dark adaptability impairment might be potentially dangerous in certain situations such as driving from the bright sun into a dark tunnel or night driving.
Dermatological disorders, such as skin and mucosal dryness, pruritus and urticaria can be detected in about 18% of subjects. Mild gastrointestinal symptoms are reported in around 13% of patients. Interestingly, with the exception of ocular surface disorders, the incidence of the other adverse effects seems to decrease with time and is significantly more frequent in postmenopausal women.
Liver toxicity and increase in blood lipid levels, especially triglycerides, are reported but not consistently in the literature.
Like other retinoids, fenretinide may be potentially teratogenic, although available studies show no genotoxic effects in vitro and in vivo, and a lack of storage in the human embryo.
Thus, appropriate measures of contraception should be adopted when treating potentially fertile women.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 3|
|Study Design ICMJE||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
|Condition ICMJE||High-Risk Cancer|
|Study Arm (s)||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE||764|
|Estimated Completion Date||December 2024|
|Estimated Primary Completion Date||December 2024 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||20 Years to 46 Years|
|Accepts Healthy Volunteers||No|
|Listed Location Countries ICMJE||Italy|
|Removed Location Countries|
|NCT Number ICMJE||NCT01479192|
|Other Study ID Numbers ICMJE||IEO S462/109, 2009-010260-41|
|Has Data Monitoring Committee||No|
|Responsible Party||European Institute of Oncology|
|Study Sponsor ICMJE||European Institute of Oncology|
|Collaborators ICMJE||Not Provided|
|Information Provided By||European Institute of Oncology|
|Verification Date||June 2014|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP